Bioage Labs, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

24 Mar 2026

BIOA

10-K: BioAge Labs Reports Positive BGE-102 Phase 1 Data, Funds Operations Through 2029

BioAge Labs, Inc. announced positive interim Phase 1 data for its lead program BGE-102, demonstrating significant hsCRP reduction, and confirmed sufficient capital to fund operations through 2029.

NASDAQ

20 Mar 2025

BIOA

Bioage Labs, INC

10-K: BioAge Labs Announces 10-K Filing: Focus Shifts to BGE-102 for Obesity Treatment

BioAge Labs files its 10-K, highlighting a strategic shift towards BGE-102, an NLRP3 inhibitor, for obesity treatment after discontinuing azelaprag development.